Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OTLC |
---|---|---|
09:32 ET | 10000 | 0.029 |
09:39 ET | 64490 | 0.0252 |
09:51 ET | 20000 | 0.024 |
10:27 ET | 5000 | 0.02575 |
10:29 ET | 1000 | 0.02575 |
10:33 ET | 500 | 0.026 |
11:02 ET | 114990 | 0.02725 |
11:03 ET | 87000 | 0.027 |
11:05 ET | 20000 | 0.02705 |
11:18 ET | 3000 | 0.028 |
11:23 ET | 50000 | 0.027 |
11:59 ET | 23000 | 0.0279 |
12:01 ET | 59000 | 0.0285 |
12:03 ET | 20000 | 0.0293 |
12:24 ET | 5000 | 0.02915 |
12:26 ET | 22000 | 0.02921 |
12:44 ET | 57500 | 0.02915 |
12:46 ET | 25000 | 0.02915 |
12:48 ET | 40000 | 0.029225 |
12:50 ET | 80000 | 0.02915 |
12:57 ET | 50000 | 0.03 |
01:02 ET | 20000 | 0.0306 |
01:15 ET | 20000 | 0.03 |
01:18 ET | 56141 | 0.03 |
01:20 ET | 10000 | 0.02908 |
01:29 ET | 130000 | 0.029 |
01:51 ET | 500 | 0.0295 |
03:30 ET | 12728 | 0.03 |
03:57 ET | 138171 | 0.029 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oncotelic Therapeutics Inc | 11.8M | -9.4x | --- |
Kazia Therapeutics Ltd | 18.1M | -0.7x | --- |
Imunon Inc | 11.8M | -0.4x | --- |
Biora Therapeutics Inc | 11.5M | 0.0x | --- |
Indaptus Therapeutics Inc | 12.1M | -0.6x | --- |
Protext Mobility Inc | 12.3M | 0.0x | --- |
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company has eight primary drug and AI technology programs: AL-101, an intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P, a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503, a second generation VDA for the treatment of liquid tumors with focus on childhood leukemia; OT-101, an antisense against TGF-β2 for the treatment of various cancers and viruses, including SARS and the COVID-19, and Artemisini, a natural derivative from an Asian herb Artemisia Annua that inhibits the ability of various viruses to multiply.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.8M |
---|---|
Revenue (TTM) | $70.0K |
Shares Outstanding | 406.3M |
Oncotelic Therapeutics Inc does not pay a dividend. | |
Beta | -0.27 |
EPS | $0.00 |
Book Value | $0.03 |
P/E Ratio | -9.4x |
Price/Sales (TTM) | 168.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,177.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.